LOGIN  |  REGISTER
Terns Pharmaceuticals

atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

September 14, 2023 | Last Trade: US$2.69 0.07 2.48

NEW YORK and BERLIN, Sept. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Cantor Fitzgerald Global Healthcare Conference.

Details of the company’s participation is as follows:

2023 Cantor Fitzgerald Global Healthcare Conference

Format: Fireside Chat

Date and Time: Thursday, September 28th at 1:50 P.M. ET

Location: New York, NY

A webcast of the company’s fireside chat will be available on atai’s website under Events on the Investors section of the atai website: https://ir.atai.life/news-events/events/. A replay will be available following the live event.

About atai Life Sciences

atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and was founded as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients.

atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit www.atai.life.

Contact Information

Investor Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page